Reviewed,
UniProtKB/Swiss-Prot Q01844 (EWS_HUMAN)
Last modified
November 25, 2008.
Version 106.
History...
Clusters with 100%,
90%,
50% identity |
Documents (4) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: RNA-binding protein EWS Alternative name(s): EWS oncogene Ewing sarcoma breakpoint region 1 protein | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 656 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is not processed. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Might normally function as a repressor. EWS-fusion-proteins (EFPS) may play a role in the tumorigenic process. They may disturb gene expression by mimicking, or interfering with the normal function of CTD-POLII within the transcription initiation complex. They may also contribute to an aberrant activation of the fusion protein target genes. |
| Subunit structure | Binds POLR2C, SF1, calmodulin and RNA. Interacts with PTK2B/FAK2. |
| Subcellular location | Nucleus. Cytoplasm. Cell surface. Note= Relocates from cytoplasm to ribosomes upon PTK2B/FAK2 activation. |
| Tissue specificity | Ubiquitous. |
| Domain | EWS activation domain (EAD) functions as a potent activation domain in EFPS. EWSR1 binds POLR2C but not POLR2E or POLR2G, whereas the isolated EAD binds POLR2E and POLR2G but not POLR2C. Cis-linked RNA-binding domain (RBD) can strongly and specifically repress trans-activation by the EAD. |
| Post-translational modification | Phosphorylated; calmodulin-binding inhibits phosphorylation of Ser-266. |
| Involvement in disease | Chromosomal aberrations involving EWSR1 are a cause of Ewing sarcoma [MIM:133450]. Translocation t(11;22)(q24;q12) with FLI1; translocation t(7;22)(p22;q12) with ETV1; translocation t(21;22)(q22;q12) with ERG; translocation t(9;22)(q22-31;q11-12) with NR4A3. Translocation t(2;21;22)(q23;q22;q12) that forms a EWSR1-FEV fusion protein with potential oncogenic activity. A chromosomal aberration involving EWSR1 is associated with desmoplastic small round cell tumor (DSRCT). Translocation t(11;22)(p13;q12) with WT1. A chromosomal aberration involving EWSR1 is associated with malignant melanoma of soft parts (MMSP). Translocation t(12;22)(q13;q12) with ATF-1. Malignant melanoma of soft parts, also known as soft tissue clear cell sarcoma, is a rare tumor developing in tendons and aponeuroses. A chromosomal aberration involving EWSR1 is associated with small round cell sarcoma. Translocation t(11;22)(p36.1;q12) with PATZ1. |
| Miscellaneous | EFPS arise due to chromosomal translocations in which EWSR1 is fused to a variety of cellular transcription factors. EFPS are very potent transcriptional activators dependent on the EAD and a C-terminal DNA-binding domain contributed by the fusion partner. The spectrum of malignancies associated with EFPS are thought to arise via EFP-induced transcriptional deregulation, with the tumor phenotype specified by the EWSR1 fusion partner and cell type. Transcriptional repression of the transforming growth factor beta type II receptor (TGF beta RII) is an important target of the EWS-FLI1, EWS-ERG, or EWS-ETV1 oncogene. Binds calmodulin in the presence, but not in the absence, of calcium ion. |
| Sequence similarities | Belongs to the RRM TET family. Contains 1 IQ domain. Contains 1 RanBP2-type zinc finger. Contains 1 RRM (RNA recognition motif) domain. |
Ontologies
Binary interactions
With | Entry | #Exp. | IntAct | Notes |
|---|---|---|---|---|
| ARHGDIA | P52565 | 1 | EBI-739737,EBI-712693 | |
| CD2BP2 | O95400 | 1 | EBI-739737,EBI-768015 | |
| GSK3B | P49841 | 1 | EBI-739737,EBI-373586 | |
| ILK | Q13418 | 1 | EBI-739737,EBI-747644 | |
| NDRG1 | Q92597 | 1 | EBI-739737,EBI-716486 | |
| PUF60 | Q9UHX1 | 1 | EBI-739737,EBI-1053259 | |
| RASSF1 | Q9NS23-2 | 1 | EBI-739737,EBI-438698 | |
| SMNDC1 | O75940 | 1 | EBI-739737,EBI-1052641 | |
| ZNF165 | P49910 | 1 | EBI-739737,EBI-741694 |
Alternative products
| This entry describes 2 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform EWS (identifier: Q01844-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform EWS-B (identifier: Q01844-2) The sequence of this isoform differs from the canonical sequence as follows: 266-338: Missing. | ||||||
| Notes: No experimental confirmation available. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chain | 1 – 656 | 656 | RNA-binding protein EWS | PRO_0000081586 | |||||||||||||||||||||
Regions | |||||||||||||||||||||||||
| Repeat | 8 – 16 | 9 | 1 | ||||||||||||||||||||||
| Repeat | 17 – 27 | 11 | 2 | ||||||||||||||||||||||
| Repeat | 28 – 34 | 7 | 3 | ||||||||||||||||||||||
| Repeat | 35 – 42 | 8 | 4 | ||||||||||||||||||||||
| Repeat | 43 – 50 | 8 | 5 | ||||||||||||||||||||||
| Repeat | 51 – 59 | 9 | 6 | ||||||||||||||||||||||
| Repeat | 60 – 68 | 9 | 7 | ||||||||||||||||||||||
| Repeat | 69 – 75 | 7 | 8 | ||||||||||||||||||||||
| Repeat | 76 – 84 | 9 | 9 | ||||||||||||||||||||||
| Repeat | 85 – 91 | 7 | 10 | ||||||||||||||||||||||
| Repeat | 92 – 110 | 19 | 11 | ||||||||||||||||||||||
| Repeat | 111 – 116 | 6 | 12 | ||||||||||||||||||||||
| Repeat | 117 – 125 | 9 | 13 | ||||||||||||||||||||||
| Repeat | 126 – 156 | 31 | 14 | ||||||||||||||||||||||
| Repeat | 157 – 163 | 7 | 15 | ||||||||||||||||||||||
| Repeat | 164 – 170 | 7 | 16 | ||||||||||||||||||||||
| Repeat | 171 – 177 | 7 | 17 | ||||||||||||||||||||||
| Repeat | 178 – 188 | 11 | 18 | ||||||||||||||||||||||
| Repeat | 189 – 193 | 5 | 19 | ||||||||||||||||||||||
| Repeat | 194 – 201 | 8 | 20 | ||||||||||||||||||||||
| Repeat | 202 – 206 | 5 | 21 | ||||||||||||||||||||||
| Repeat | 207 – 212 | 6 | 22 | ||||||||||||||||||||||
| Repeat | 213 – 218 | 6 | 23 | ||||||||||||||||||||||
| Repeat | 219 – 224 | 6 | 24 | ||||||||||||||||||||||
| Repeat | 225 – 230 | 6 | 25 | ||||||||||||||||||||||
| Repeat | 231 – 238 | 8 | 26 | ||||||||||||||||||||||
| Repeat | 239 – 245 | 7 | 27 | ||||||||||||||||||||||
| Repeat | 246 – 252 | 7 | 28 | ||||||||||||||||||||||
| Repeat | 253 – 259 | 7 | 29 | ||||||||||||||||||||||
| Domain | 256 – 285 | 30 | IQ | ||||||||||||||||||||||
| Repeat | 260 – 276 | 17 | 30 | ||||||||||||||||||||||
| Repeat | 277 – 285 | 9 | 31 | ||||||||||||||||||||||
| Domain | 361 – 447 | 87 | RRM | ||||||||||||||||||||||
| Zinc finger | 518 – 549 | 32 | RanBP2-type | ||||||||||||||||||||||
| Region | 1 – 285 | 285 | EAD (Gln/Pro/Thr-rich) | ||||||||||||||||||||||
| Region | 8 – 285 | 278 | 31 X approximate tandem repeats | ||||||||||||||||||||||
| Compositional bias | 300 – 340 | 41 | Arg/Gly/Pro-rich | ||||||||||||||||||||||
| Compositional bias | 454 – 513 | 60 | Arg/Gly/Pro-rich | ||||||||||||||||||||||
| Compositional bias | 559 – 640 | 82 | Arg/Gly/Pro-rich | ||||||||||||||||||||||
Sites | |||||||||||||||||||||||||
| Site | 348 – 349 | 2 | Breakpoint for insertion to form EWSR1-FEV fusion protein | ||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||
| Modified residue | 266 | 1 | Phosphoserine; by PKC By similarity | ||||||||||||||||||||||
| Modified residue | 300 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 302 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 304 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 309 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 314 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 317 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 321 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 455 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 464 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 471 | 1 | Asymmetric dimethylarginine; alternate | ||||||||||||||||||||||
| Modified residue | 471 | 1 | Omega-N-methylarginine; alternate | ||||||||||||||||||||||
| Modified residue | 490 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 494 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 500 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 503 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 506 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 563 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 565 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 572 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 575 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 581 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 589 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 592 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 596 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 600 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 603 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 607 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 615 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 633 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
| Modified residue | 636 | 1 | Asymmetric dimethylarginine | ||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||
| Alternative sequence | 266 – 338 | 73 | Missing in isoform EWS-B. | VSP_005793 | |||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||
| Beta strand | 362 – 366 | 5 | |||||||||||||||||||||||
| Helix | 374 – 381 | 8 | |||||||||||||||||||||||
| Turn | 382 – 384 | 3 | |||||||||||||||||||||||
| Beta strand | 391 – 393 | 3 | |||||||||||||||||||||||
| Beta strand | 396 – 399 | 4 | |||||||||||||||||||||||
| Turn | 404 – 406 | 3 | |||||||||||||||||||||||
| Beta strand | 411 – 419 | 9 | |||||||||||||||||||||||
| Helix | 420 – 430 | 11 | |||||||||||||||||||||||
| Beta strand | 441 – 443 | 3 | |||||||||||||||||||||||
Sequences
| ||||||||||||||||||||||||

Clusters with